References
European Public Assessment Reports (EPARs) for authorised medicinal products for human use. Protelos. Press Release (2007) Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/PressRelease_Protelos_41745807en.pdf
European Public Assessment Reports (EPARs) for authorised medicinal products for human use. Protelos. Product information. Annex I—summary of product characteristics. Section 4.4, 4.8. (2008) Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/H-560-PI-en.pdf
European Public Assessment Reports (EPARs) for authorised medical products for human use. Osseor. Product information. Annex I—summary of product characteristics. Section 4.4, 4.8. (2008) Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/osseor/H-561-PI.en.pdf
Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822
Conflicts of interest
Our centre has received an educational grant from Servier to perform research on strontium ranelate.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pernicova, I., Middleton, E.T. & Aye, M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 19, 1811–1812 (2008). https://doi.org/10.1007/s00198-008-0734-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-008-0734-8